PMC9300950_01
Tumor progression of the patient with postoperative liver metastases from hilar cholangiocarcinoma. (A) The timeline of therapies and tumor progression are indicated. (B) Line chart showing changes in the levels of the tumor marker CA 19-9 during the course of treatment. (C-E) MR scan of the lesion in the bile duct before and after 2 and 4 months of capecitabine plus trastuzumab treatment. MR, magnetic resonance; CA 19-9, cancer antigen 19-9.
fonc-12-918297-g001.jpg
PMC9300950_01_fonc-12-918297-g001.jpg
f1
In addition, the levels of serum tumor markers were significantly reduced during the treatment ( Figure 1 ).